Shajini
VB Spine Completes Acquisition of Stryker’s Cestas Manufacturing Facility Pulse: Anavex Receives Constructive FDA Feedback on Alzheimer’s Disease Program Pulse: Newleos Therapeutics Doses First Patient in Phase 2 SOAR Study for Social Anxiety Disorder Pulse: Lysoway Therapeutics Advances LW-1017 to Phase I Readiness in Neurodegeneration Pulse: LoQus23 Nominates LQT-23 as First-in-Class Oral Drug Candidate for … Read more
UK biotech Ikarovec teams with VectorBuilder on eye gene delivery.
Daily neurology update covering Alzheimer’s, Parkinson’s, epilepsy, ADHD.
NICE backs natalizumab for highly active relapsing MS.
NICE proposes age-based CA125 testing to improve early diagnosis.
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
NeuroPulse: Today’s Three Signals The neurology sector delivered three distinct signals today, spanning device-led personalization, regulatory expansion in pediatric imaging, and strategic recalibration in neuropsychiatric drug development. Together, they highlight how execution, not novelty, is increasingly determining momentum across neuroscience. Signal One: Soin Neuroscience and BIOTRONIK Push Spinal Cord Stimulation Toward Personalization Soin Neuroscience and … Read more